ArticleNeuro-oncology2016
Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Review
- Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?International journal of molecular sciences · 2024Review
- Impact of glioma metabolism-related gene ALPK1 on tumor immune heterogeneity and the regulation of the TGF-β pathway.Frontiers in immunology · 2024Article
- Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.Frontiers in pharmacology · 2023Review
- TGF-β based risk model to predict the prognosis and immune features in glioblastoma.Frontiers in neurology · 2023Article
- Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.Neuro-oncology · 2022Article
- Bone morphogenetic protein receptor inhibitors suppress the growth of glioblastoma cells.Molecular and cellular biochemistry · 2022Article
- Integrin subunit alpha V is a potent prognostic biomarker associated with immune infiltration in lower-grade glioma.Frontiers in neurology · 2022Article
- Altered BMP2/4 Signaling in Stem Cells and Their Niche: Different Cancers but Similar Mechanisms, the Example of Myeloid Leukemia and Breast Cancer.Frontiers in cell and developmental biology · 2021Review
- The Role of Neurodevelopmental Pathways in Brain Tumors.Frontiers in cell and developmental biology · 2021Review
- γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression.International journal of medical sciences · 2021Article
- A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression.Scientific reports · 2020Article
- Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.Bioorganic & medicinal chemistry letters · 2020Article
- Article
- ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.Nature communications · 2019Article
- Pharmacologic Strategies for Assaying BMP Signaling Function.Methods in molecular biology (Clifton, N.J.) · 2019Article
- SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.Molecular and cellular biochemistry · 2017Article
- Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells.Oncogene · 2017Article
- Differential molecular regulation of processing and membrane expression of Type-I BMP receptors: implications for signaling.Cellular and molecular life sciences : CMLS · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Laura D HoverDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Philip OwensDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Alexander L MundenDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Jialiang WangDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Lola B ChamblessDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Corey R HopkinsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Charles C HongDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Harold L MosesDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Ty W AbelDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (L.D.H., T.W.A.); Department of Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (P.O., H.L.M.); Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee (A.M.); Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee (J.W., L.C.); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (C.H.); Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center (C.C.H.); Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee (C.C.H.); Research Medicine, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee (C.C.H.).
Neurological Surgery · USVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MUnderstanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0MCardiac Induction by Small Molecule BMP InhibitorsR01HL104040 · NHLBI · VANDERBILT UNIVERSITY · PI HONG, CHARLES C · 2010 to 2014
$2.0MTargeting Radiation Resistance in Glioblastoma Stem CellsR01CA166492 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREEMAN, MICHAEL L. · 2013 to 2017
$1.6MTGF-Beta, Neural Stem Cella and GliomagenesisK08NS062107 · NINDS · VANDERBILT UNIVERSITY · PI ABEL, TY WILLIAM · 2008 to 2012
$838kNCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA166492NHLBI NIH HHS R01 HL104040NIDDK NIH HHS P30 DK058404NIGMS NIH HHS P50 GM115305NINDS NIH HHS K08 NS062107
Abstract
backgroundImproved therapies for high-grade glioma (HGG) are urgently needed as the median survival for grade IV gliomas is only 15 months. Bone morphogenetic protein (BMP) signaling plays critical and complex roles in many types of cancer, including glioma, with most of the recently published work focusing on BMP-mediated regulation of glioma stem cells (GSCs). We hypothesized that BMP signaling may be an important modulator of tumorigenic properties in glioma cells outside of the GSC compartment.
methodsWe used a human HGG tissue microarray and performed immunohistochemistry for phospho-Smads1,5,8. To examine the role of BMP signaling in tumorigenic astrocytes, transgenic mice were used to delete the BMP type IA receptor (Bmpr1a) and generate astrocytes transformed with oncogenic Ras and homozygous deletion of p53. The cells were transplanted orthotopically into immunocompetent adult host mice.
resultsFirst we established that BMP signaling is active within the vast majority of HGG tumor cells. Mice implanted with BMPR1a-knockout transformed astrocytes showed an increase in median survival compared with mice that received BMPR1a-intact transformed astrocytes (52.5 vs 16 days). In vitro analysis showed that deletion of BMPR1a in oncogenic astrocytes resulted in decreased proliferation, decreased invasion, decreased migration, and increased expression of stemness markers. In addition, inhibition of BMP signaling in murine cells and astrocytoma cells with a small molecule BMP receptor kinase inhibitor resulted in similar tumor suppressive effects in vitro.
conclusionBMP inhibition may represent a viable therapeutic approach in adult HGG.
Indexed as
Signal TransductionAnimalsAstrocytesBone Morphogenetic Protein Receptors, Type IBone Morphogenetic ProteinsCarcinogenesisCell ProliferationCell Transformation, NeoplasticGene Expression RegulationGliomaMice, TransgenicBmpr1a protein, mouseBone Morphogenetic Protein Receptors, Type IBone Morphogenetic ProteinsBMPBMPR1aDMH1genetically engineered micehigh-grade glioma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.